Related Experiment Video
Updated: Jan 9, 2026

07:30
A Simple Approach to Induce Experimental Autoimmune Neuritis in C57BL/6 Mice for Functional and Neuropathological Assessments
Published on: November 9, 2017
10.0K
[Acute inflammatory demyelinating polyneuropathy (Guillain-Barré syndrome)]
V V Swistunov1,2, E I Dzhoga1
1Irkutsk City Clinical Hospital No. 1, Irkutsk, Russia.
Arkhiv Patologii
|December 2, 2025
Summary
Guillain-Barré syndrome, an immune disorder causing acute paralysis, involves varied structural changes. This study reviews clinical data and morphological findings to better understand the condition.
Area of Science:
- Neurology
- Immunology
- Pathology
Background:
- Guillain-Barré syndrome is a rare, acute immune-mediated polyradiculoneuropathy.
- It is a leading cause of acute paralysis, necessitating intensive care in a third of patients.
- Morphological descriptions are limited due to the condition's rarity and low mortality.
Purpose of the Study:
- To analyze clinical data, treatment strategies, and structural changes in Guillain-Barré syndrome.
- To consolidate existing literature with original observations for a comprehensive overview.
- To elucidate the nature of morphological alterations through advanced study techniques.
Main Methods:
- Literature review of Guillain-Barré syndrome cases.
- Analysis of own clinical observations and treatment outcomes.
- Histochemical and immunohistochemical examination of tissue samples.
Main Results:
- Detailed analysis of clinical presentations and therapeutic responses.
- Characterization of morphological changes using routine, histochemical, and immunohistochemical methods.
- Correlation of clinical findings with pathological alterations.
Conclusions:
- Guillain-Barré syndrome presents diverse clinical and morphological features.
- Comprehensive analysis aids in understanding disease mechanisms and improving patient management.
- Further research into structural changes can refine diagnostic and therapeutic approaches.
Related Concept Videos
Myasthenia Gravis: Diagnostic Tests
1.9K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
1.9K
Myasthenia Gravis: Overview and Treatment
2.7K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.7K
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
326
Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
326
Chemical Synapses
11.1K
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
11.1K

